PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine
J Rosenblatt, B Glotzbecker, H Mills… - Journal of …, 2011 - journals.lww.com
We have developed a cancer vaccine in which autologous tumor is fused with dendritic cells
(DCs) resulting in the presentation of tumor antigens in the context of DC-mediated
costimulation. In clinical trials, immunologic responses have been observed, however
responses may be muted by inhibitory pathways. The PD1/PDL1 pathway is an important
element contributing to tumor-mediated immune suppression. In this study, we demonstrate
that myeloma cells and DC/tumor fusions strongly express PD-L1. Compared with a control …
(DCs) resulting in the presentation of tumor antigens in the context of DC-mediated
costimulation. In clinical trials, immunologic responses have been observed, however
responses may be muted by inhibitory pathways. The PD1/PDL1 pathway is an important
element contributing to tumor-mediated immune suppression. In this study, we demonstrate
that myeloma cells and DC/tumor fusions strongly express PD-L1. Compared with a control …